Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours

Journal of Clinical Pathology - Clinical Molecular Pathology

Volumn 49, Issue 4, 1996, Pages

  Terris, B ^a   Flejou J F ^a   Dubois, S ^a   Ruszniewski, P ^a   Scoazec, J Y ^a   Belghiti, J ^a   Potet, F ^b   Bernades, P ^b   Mignon, M ^b   Henin D ^b  

^a BEAUJON HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Alternative splicing; CD44; Neuroendocrine tumours; Pancreas

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ARTICLE; CARCINOID; CLINICAL ARTICLE; ENDOCRINE TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE TUMOR; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 18344416068     PISSN: 13552910     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.49.4.m203     Document Type: Article

References (33)

1. Klöppel G, Heitz PU. Pancreatic endocrine tumours. Palhol Res Pract 1988;183:155-8.
2. Kenny BD, Sloan JM, Hamilton PW, Watt PCH, Johnston CF, Buchanan KD. The role of morphometry in predicting prognosis in pancreatic endocrine tumours. Cancer 1989;64:460-5.
3. Pelosi G, Zamboni G, Doglioni C, Rodella S, Bresaola E, lacono C, et al. Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine pancreatic tumours of the pancreas. Am J Surg Pathol 1992;16:1215-25.
4. Von Herbay A, Sieg B, Schürmann G, Hofmann WJ, Betzier M, Otto HF. Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations. Gr 1991;32:949-53.
5. Metz DC, Kuchnio M, Fraker DL, Venzon DJ, Jaffe G, Jensen RT, et al. Flow cytometry and Zollinger-Ellison syndrome: Relationship to clinical course. Gastroenterologv 1993;105:799-813.
6. Chaudhry A, Oberg K. Expression of growth factor peptides and adhesion molecules in endocrine pancreatic tumours. In: Mignon M, Jensen RT, eds. Endocrine tumours of the pancreas. Front Gastrointestinal Res. Vol 23. Basel: Karger, 1994:132-46.
7. Gunthert U, Hofman R, Rudy W, Reber S, Zoller M, Haubmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65:13-24.
8. Seiter S, Arch R, Reber S, Komitowski K, Hofman M, Ponta H, et al. Prevention of tumour metastasis formation by anti-variant CD44. J Exp Med 1993;177:443-55.
9. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992;340:1053-8.
10. Tanabe KK, Ellis LM, Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and métastases. Lancet 1993;341:725-6.
11. Finn L, Becich M, Dougherty G, Finley G, Meisler A, Cooper D. CD44 alternative splicing in human colon carcinomas. Lab Invest 1993;68: 49A.
12. Heider KH, Hoftnann M, Van den Berg F, Ponta H, Herrlich P, Pals ST. A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993;120:227-33.
13. Mulder JWR, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994;344:1470-2.
14. Terpe HJ, Koopmann R, Imhof BA, Günthert U. Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Paihol 1994;174:89-100.
15. Chaudhry A, Gobi A, Eriksson B, Skogseid B, Öberg K. Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumours. Cancer Res 1994;54:981-6.
16. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KG, Harris AL, et al. Normal human tissues, in addition to some tumours, express multiple different CD44 isoforms. Cancer Res 1994;54:4539-46.
17. Koopman G, Heider KH, Horst E, Adolf GR, Van Den Berg F, Ponta F, et al. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J ExpMed 1993;177:897-904.
18. Mason DY, Sammons RE. The labelled antigen method of immunoenzymatic staining. J Histochem Cytochem 1979; 27:832-40.
19. Graham RC, Karnovski MJ. The early stages of absorption of horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histochem Cytochem 1966;14:291-302.
20. Fujita N, Yaegashi N, Ide Y, Sato S, Nakamura M, Ishiwata I, et al. Expression of CD44 in normal human versus tumour endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 1994;54:3922-8.
21. Kaufmann M, Heider KH, Sinn HP, Minckwitz G, Ponta H, Herrlich P. CD44 variant epitopes in primary breast cancer and length of survival. Lancet 1995;345:615-19.
22. Mulder JWR, Wielenga VJM, Polak MM, van den Berg FM, Adolf GR, Herrlich P, et al. Expression of mutant p53 protein and CD44 variant proteins in colorectal tumourigenesis. Gut 1995;36:76-80.
23. Mayer B, Jauch KW, Günthert U, Figdor CG, Schildberg FW, Funke I, et al. De-novo expression of CD44 and survival in gastric cancer. Lancet 1993;342:1019-22.
24. Harn HJ, Ho LI, Chang JY, Wu CW, Jiang SY, Lee HS, et al. Differential expression of the human metastasis adhesion molecule CD44v in normal and carcinomatous stomach mucosa of Chinese subjects. Cancer 1995;7S:1065-71
25. Washington K, Gottfried MR, Telen MJ. Expression of the cell adhesion molecule CD44 in gastric adenocarcinoma. Hum Pathol 1994;25:1043-9.
26. Dali P, Heider KH, Sinn HP, Skroch-Angel P, Adolf G, Kaufmann M, et al. Comparison of immunohistochemistry and RT-PCRfor detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 1995;60:471-7.
27. Matsumara Y, Sugiyama M, Matsumara S, Hayle AJ, Robinson P, Smith JC, et al. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol 1995;177:11-20.
28. Sy MS, Guo YJ, Stamenkovic I. Distincts effect of two CD44 isoforms on tumour growth in vivo. J Exp Med 1991;174:859-66.
29. Thomas L, Byers HR, Vink J, Stamenkovic I. CD44H regulates tumour cell migration on hyaluronate-coated substrate. J Cell Biol 1992;118:971-7.
30. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 1993;53:3830-8.
31. Shtivelman E, Bishop JM. Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 1991;ll:5446-53.
32. Penno MB, Thomas August J, Baylin SB, Mabry M, Ilona Linnoila R, Lee VS, et al. Expression of CD44 in human lung tumours. Cancer Res 1994;S4:1381-7.
33. lida N, Bourguignon LYW. New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995; 162:127-33.